Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Pharmacokinetics
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Product description Product information Pharmacology

Pharmacokinetics

2 evidence topics · 1 source

Systemic pharmacokinetics after intravitreal injection

“Following intravitreal administration of LYTENAVA, the systemic exposure to bevacizumab-vikg is minimal.” (opens the prescribing information at this quote)
“In 14 subjects who received a single 1.25 mg dose of LYTENAVA, the serum bevacizumab-vikg concentration was assessed up to Day 4. The serum bevacizumab-vikg concentrations gradually increased over time, so the highest concentrations observed were approximately at Day 4 (the last collection time) ranging from 33 to 270 ng/mL, which was <1% of the Cmax after intravenous infusion of 2 mg/kg bevacizumab-vikg. However, due to the limited sample collection, Cmax or AUC could not be adequately characterized.” (opens the prescribing information at this quote)

Immunogenicity

“The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of LYTENAVA or of other bevacizumab products.” (opens the prescribing information at this quote)
“In a 52-week study, a total of 14 subjects who received LYTENAVA and were subsequently evaluated for immunogenicity did not show detectable ADA at any timepoint but the ADA assay sensitivity data in the presence of free drug was insufficient. However, due to the minimal systemic exposure to LYTENAVA following intravitreal injection, the risk of immunogenicity is not expected to be clinically significant.” (opens the prescribing information at this quote)